Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug 26:37:13593.
doi: 10.3389/ti.2024.13593. eCollection 2024.

Transplant Trial Watch

Simon R Knight  1   2 , John Fallon  1 , Reshma Rana Magar  1
Affiliations
Editorial

Transplant Trial Watch

Simon R Knight et al. Transpl Int. .
No abstract available

Keywords: antibody mediated rejection (ABMR); delayed graft function; kidney transplantation (KT); randomised controlled trial; systematic review/meta-analysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, et al. Recommended Treatment for Antibody-Mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus FROM the Transplantion Society Working Group. Transplantation (2020) 104:911–22. 10.1097/TP.0000000000003095 - DOI - PMC - PubMed
    1. Bailly E, Ville S, Blancho G, Morelon E, Bamoulid J, Caillard S, et al. An Extension of the RITUX-ERAH Study, Multicenter Randomized Clinical Trial Comparing Rituximab to Placebo in Acute Antibody-Mediated Rejection After Renal Transplantation. Transpl Int Official J Eur Soc Organ Transpl (2020) 33:786–95. 10.1111/tri.13613 - DOI - PubMed
    1. Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, et al. A Randomized Trial of Bortezomib in LATE Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol JASN (2018) 29:591–605. 10.1681/ASN.2017070818 - DOI - PMC - PubMed
    1. Nickerson PW, Böhmig GA, Chadban S, Kumar D, Mannon RB, van Gelder T, et al. Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection (AMR) in Kidney Transplant Recipients: Phase 3 IMAGINE Study Rationale and Design. Trials (2022) 23:1042. 10.1186/s13063-022-06897-3 - DOI - PMC - PubMed
    1. Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, et al. A Randomized Clinical Trial of Anti–IL-6 Antibody Clazakizumab in LATE Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol : JASN (2021) 32:708–22. 10.1681/ASN.2020071106 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources